PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases (CDK)4 and CDK6 with ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. To identify predictors of response, we determined the in vitro sensitivity to PD 0332991 across a panel of molecularly characterized human breast cancer cell lines. METHODS: Forty-seven human breast cancer and immortalized cell lines representing the known molecular subgroups of breast cancer were treated with PD 0332991 to determine IC50 values. These data were analyzed against baseline gene expression data to identify genes associated with PD 0332991 response. RESULTS: Cell lines representing luminal estrogen receptor-positive (ER+) subtype (including those that are HER2 amplified) were most sensitive to growth inhibition by PD 0332991 while nonluminal/basal subtypes were most resistant. Analysis of variance identified 450 differentially expressed genes between sensitive and resistant cells. pRb and cyclin D1 were elevated and CDKN2A (p16) was decreased in the most sensitive lines. Cell cycle analysis showed G0/G1 arrest in sensitive cell lines and Western blot analysis demonstrated that Rb phosphorylation is blocked in sensitive lines but not resistant lines. PD 0332991 was synergistic with tamoxifen and trastuzumab in ER+ and HER2-amplified cell lines, respectively. PD 0332991 enhanced sensitivity to tamoxifen in cell lines with conditioned resistance to ER blockade. CONCLUSIONS: These studies suggest a role for CDK4/6 inhibition in some breast cancers and identify criteria for patient selection in clinical studies of PD 0332991
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In some of these models, resistance can be overcome by including CDK4/6 inhibitors in the treatment (Finn et al., 2009; Goel et al., 2016; Kwong et al., 2012; Vora et al., 2014; Zhou et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2009
In the citing paper
“Preclinical data utilizing palbociclib demonstrated the substantial sensitivity of hormone receptor (HR)-positive cell lines, compared to HR-negative cell lines, in part related to a higher incidence of RB-negativity in the latter breast cancer subgroup (81).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab has been shown to have clinical activity in HER2amplified breast cancer [34].”
BackgroundSelf-citationSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“Multiple drug effect analysis was performed using computer software as previously described [33].”
MethodA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“PD 0332991 is an orally active potent and highly selective inhibitor of CDK4 and CDK6 kinases, which in low nanomolar concentrations blocks pRb phosphorylation - subsequently inducing G1 arrest in sensitive cell lines [26-29].”
Background
Research works printed but not linked: 1
- Duchnowska RJJ Thorat MA Morimiya A Sledge GW Li L Biernat W Szczylik C Steeg PS Badve SS Gene expression analysis for prediciton of early brain metastasis in HER2-positive breast cancer patients [abstract 1019] J Clin Oncol 2008 26 20 Suppl abstract 1019
Cited by
Items 601–700 of 1,000
Peng, P., Qiang, X., Li, G., Li, L., Ni, S., Yu, Q., Sourd, L., Marangoni, E., Hu, C., Wang, D., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0012 · Cited by 29
Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania
Ionescu, A.-I., Anghel, A.-V., Barnonschi, A.-A., Mitre, R., Lișcu, H.-D., Găinariu, E., Pătru, R. I., & Coniac, S. (2023) · Diagnostics · doi:10.3390/diagnostics13111938 · Cited by 32
Emerging strategies to overcome resistance to endocrine therapy for breast cancer
Ziauddin, M. F., Hua, D., & Tang, S.-C. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9504-6 · Cited by 37
Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents
Petroni, G., & Galluzzi, L. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1889101 · Cited by 28
Deng, Y., Ma, G., Li, W., Wang, T. I., Zhao, Y., & Wu, Q. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.04.017 · Cited by 36
Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer
Luca, A. D., Maiello, M. R., D’Alessio, A., Frezzetti, D., Gallo, M., Carotenuto, M., & Normanno, N. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1514720 · Cited by 28
Catlin, N. R., Bowman, C., Engel, S., Sacaan, A. I., Thibault, S., Lewis, E. M., & Cappon, G. D. (2019) · Reproductive Toxicology · doi:10.1016/j.reprotox.2019.07.016 · Cited by 30
Li, T., Xiong, Y., Wang, Q., Chen, F., Zeng, Y., Yu, X., Wang, Y., Zhou, F., & Zhou, Y. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1670670 · Cited by 35
Gagliato, D. D. M., Buzaid, A. C., Pérez-García, J. M., Llombart‐Cussac, A., & Cortés, J. (2020) · Cancers · doi:10.3390/cancers12092480 · Cited by 29
MZB1 expression indicates poor prognosis in estrogen receptor‑positive breast cancer
Watanabe, M., Shibata, M., Inaishi, T., Ichikawa, T., Soeda, I., Miyajima, N., Takano, Y., Takeuchi, D., Tsunoda, N., Kanda, M., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.12059 · Cited by 31
Gianni, L., Colleoni, M. A., Bisagni, G., Mansutti, M., Zamagni, C., Mastro, L. D., Zambelli, S., Bianchini, G., Frassoldati, A., Maffeis, I., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-021-00377-8 · Cited by 28
Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST
Schaefer, I., Hemming, M. L., Lundberg, M. Z., Serrata, M. P., Goldaracena, I., Liu, N., Yin, P., Paulo, J. A., Gygi, S. P., George, S., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01990-5 · Cited by 31
Tsuji, J., Li, T., Grinshpun, A., Coorens, T. H. H., Russo, D., Anderson, L., Rees, R., Nardone, A., Patterson, C., Lennon, N. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2305 · Cited by 32
Nabieva, N., & Fasching, P. A. (2023) · Cancers · doi:10.3390/cancers15061763 · Cited by 29
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
Bayani, J., Yao, C. Q., Quintayo, M. A., Yan, F., Haider, S. A., D’Costa, A., Brookes, C. L., van de Velde, C. J. �., Hasenburg, A., Kieback, D., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-016-0003-5 · Cited by 37
PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications
Pravin, N., & Jóźwiak, K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116837 · Cited by 32
Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues
Marei, H. E. S., Bedair, K., Hasan, A., Al-Mansoori, L., Gaiba, A., Morrione, A., Cenciarelli, C., & Giordano, A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00931-8 · Cited by 42
Durability of Kinase-Directed Therapies—A Network Perspective on Response and Resistance
Murray, B. W., & Miller, N. L. G. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0088 · Cited by 29
Ni, Y., Schmidt, K. R., Werner, B. A., Koenig, J. K., Guldner, I. H., Schnepp, P. M., Tan, X., Jiang, L., Host, M., Sun, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10743-7 · Cited by 28
Valenzuela, C. A., Quintanilla, R., Olate‐Briones, A., Venturini, W., Mancilla, D., Cayo, Á., Moore‐Carrasco, R., & Brown, N. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215292 · Cited by 30
Xue, Z., Lui, V. W. Y., Li, Y., Jia, L., You, C., Li, X., Piao, W., Yuan, H., Khong, P. L., Lo, K. W., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01763-z · Cited by 30
Endocrine Resistance: What Do We Know?
Miller, T. W. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e37 · Cited by 31
Therapeutic landscape of advanced HER2-positive breast cancer in 2022
Gupta, R., Gupta, S., Antonios, B., Ghimire, B., Jindal, V., Deol, J., Gaikazian, S., Huben, M. T., Anderson, J., Stender, M., et al. (2022) · Medical Oncology · doi:10.1007/s12032-022-01849-y · Cited by 35
Kim, S., & Singh, S. V. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3279-5 · Cited by 28
Ferguson, K., Yadav, A., Morey, S., Abdullah, J., Hrysenko, G., Eng, J. Y., Sajjad, M., Koury, S. T., & Rittenhouse‐Olson, K. (2014) · Future Oncology · doi:10.2217/fon.13.209 · Cited by 27
RelA-Induced Interferon Response Negatively Regulates Proliferation
Kochupurakkal, B. S., Wang, Z. C., Hua, T., Culhane, A. C., Rodig, S. J., Molek, K. R., Lazaro, J., Richardson, A. L., Biswas, D. K., & Iglehart, J. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140243 · Cited by 31
The Androgen Receptor: Is It a Promising Target?
Gucalp, A., & Traina, T. A. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-5961-9 · Cited by 27
CDK4 expression in chordoma: A potential therapeutic target
Liu, T., Shen, J. K., Choy, E., Zhang, Y., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2017) · Journal of Orthopaedic Research® · doi:10.1002/jor.23819 · Cited by 27
Abemaciclib for the treatment of breast cancer
Kotake, T., & Toi, M. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1448787 · Cited by 31
Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
Schedin, T., Borges, V. F., & Shagisultanova, E. I. (2018) · International Journal of Breast Cancer · doi:10.1155/2018/7835095 · Cited by 29
van Caloen, G., & Machiels, J. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000513 · Cited by 27
Kim, K. N., Shah, P. D., Clark, A. S., Freedman, G. M., Dastgheyb, S., Barsky, A. R., Dreyfuss, A. D., & Taunk, N. K. (2021) · The Breast · doi:10.1016/j.breast.2021.10.001 · Cited by 27
Kalous, O., Conklin, D. F., Desai, A. J., Dering, J., Goldstein, J. B., Ginther, C., Anderson, L. A., Lu, M., Kolarova, T. R., Eckardt, M. A., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2702-z · Cited by 28
Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer
Fedele, P., Orlando, L., Schiavone, P., Calvani, N., Caliolo, C., Quaranta, A., Nacci, A., & Cinieri, S. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.01.001 · Cited by 29
CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin
Tarasewicz, E., Hamdan, R., Straehla, J. P., Hardy, A. N., Lopez, O. N., Zelivianski, S., Đokić, D., & Jeruss, J. S. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29693 · Cited by 29
Nemoto, A., Saida, S., Kato, I., Kikuchi, J., Furukawa, Y., Maeda, Y., Akahane, K., Oshiro, H., Goi, K., Kagami, K., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1065 · Cited by 31
Developmental therapeutics for inflammatory breast cancer: Biology and translational directions
Costa, R. L. B., Santa-Maria, C. A., Rossi, G., Carneiro, B. A., Chae, Y. K., Gradishar, W. J., Giles, F. J., & Cristofanilli, M. (2016) · Oncotarget · doi:10.18632/oncotarget.13778 · Cited by 28
Montagna, E., & Colleoni, M. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919894105 · Cited by 28
Iorfida, M., Mazza, M., & Munzone, E. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s196240 · Cited by 33
Zacksenhaus, E., Liu, J.-K., Jiang, Z., Yao, Y., Xia, L., Shrestha, M., & Ben‐David, Y. (2016) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2016.10.003 · Cited by 30
Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer
Lee, S., & Seo, J. H. (2018) · BioMed Research International · doi:10.1155/2018/6074808 · Cited by 29
Lanceta, L., O’Neill, C. H., Lypova, N., Li, X., Rouchka, E. C., Waigel, S. J., Gómez-Gutiérrez, J. G., Chesney, J. A., & Imbert-Fernandez, Y. (2020) · Genes · doi:10.3390/genes11040467 · Cited by 27
Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology
Gümüşay, Ö., Vitiello, P. P., Wabl, C. A., Corcoran, R. B., Bardelli, A., & Rugo, H. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280845 · Cited by 33
Mekonnen, L. B., Tadesse, S., Lenjisa, J. L., Yu, M., Noll, B. D., Heinemann, G. K., Lokman, N. A., Ricciardelli, C., Oehler, M. K., Beck, A. R., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.012 · Cited by 25
Palumbo, R., Torrisi, R., Sottotetti, F., Presti, D., Gambaro, A. R., Collovà, E., Ferzi, A., Agostinetto, E., Teragni, C. M., Saltalamacchia, G., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920987651 · Cited by 26
Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study
Shao, X., Zheng, Y., Cao, W., Shen, X., Li, G., Chen, J., Huang, Y., Huang, P., Shi, L., Ye, W.-W., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1340 · Cited by 26
Kumarasamy, V. M., Nambiar, R., Wang, J., Rosenheck, H. R., Witkiewicz, A. K., & Knudsen, E. S. (2022) · Oncogene · doi:10.1038/s41388-022-02362-2 · Cited by 29
Determinants of response to CDK4/6 inhibitors in the real-world setting
Witkiewicz, A. K., Schultz, E., Wang, J., Hamilton, D., Levine, E. G., O’Connor, T. L., & Knudsen, E. S. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00438-0 · Cited by 29
Dunbar, K. L., Perlatti, B., Liu, N., Cornelius, A. R., Mummau, D., Chiang, Y., Hon, L., Nimavat, M., Pallas, J., Kordes, S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2310522120 · Cited by 26
The specific role of pRb in p16INK4A-mediated arrest of normal and malignant human breast cells
Bazarov, A. V., Lee, W. J., Bazarov, I., Bosire, M., Hines, W. C., Stankovich, B., Chicas, A., Lowe, S. W., & Yaswen, P. (2012) · Cell Cycle · doi:10.4161/cc.11.5.19492 · Cited by 33
Advances in the targeted therapy of liposarcoma
Guan, Yu, X., Wang, H., Wang, H., Zhang, J., Li, G., Cao, J., & Teng, L. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s72722 · Cited by 27
Brufsky, A. (2015) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s31586 · Cited by 31
Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo
Ramovš, V., Secades, P., Song, J., Thijssen, B., Kreft, M., & Sonnenberg, A. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1146-8 · Cited by 28
Chen, A., Kim, B.-J., Mitra, A., Vollert, C. T., Lei, J. T., Fandino, D. M., Anurag, M., Holt, M. V., Gou, X., Pilcher, J. B., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0564 · Cited by 24
SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors
Cui, Y., Li, Y., Xu, Y., Liu, X., Kang, X., Zhu, J., Long, S., Han, Y., Xue, C., Sun, Z., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103304 · Cited by 35
Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222
Dommer, A. P., Kumarasamy, V. M., Wang, J., O’Connor, T. N., Roti, M., Mahan, S., McLean, K., Knudsen, E. S., & Witkiewicz, A. K. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2244 · Cited by 28
Jérusalem, G., Bachelot, T., Barrios, C. H., Neven, P., Leo, A. D., Janni, W., & BOER, R. D. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.011 · Cited by 26
Sammons, S. L., Kornblum, N. S., & Blackwell, K. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0587-9 · Cited by 27
Shee, K., Jiang, A., Varn, F. S., Liu, S., Traphagen, N. A., Owens, P., Ma, C. X., Hoog, J., Cheng, C., Golub, T. R., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201801241r · Cited by 28
Wang, H., Li, F., Liu, N., Liu, X., Yang, X., Guo, Y., Bei, J., Zeng, Y., & Shao, J. (2019) · Cancer Medicine · doi:10.1002/cam4.2146 · Cited by 23
Durable response to palbociclib and letrozole in ovarian cancer withCDKN2Aloss
Frisone, D., Charrier, M., Clément, S., Christinat, Y., Thouvenin, L., Homicskó, K., Michielin, O. A., Bodmer, A., Chappuis, P. O., McKee, T., et al. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1685291 · Cited by 27
Lin, M., Chen, Y., Jin, Y., Hu, X., & Zhang, J. (2020) · Journal of Cancer · doi:10.7150/jca.48944 · Cited by 25
Jahan, N., Jones, C., & Rahman, R. L. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111324 · Cited by 27
Bi, H., Shang, J., Zou, X., Xu, J., & Han, Y. (2021) · Oncology Letters · doi:10.3892/ol.2021.12864 · Cited by 27
Çetin, B., Wabl, C. A., & Gümüşay, Ö. (2022) · Future Oncology · doi:10.2217/fon-2021-0842 · Cited by 25
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
Digiacomo, G., Fumarola, C., Monica, S. L., Bonelli, M. A., Cavazzoni, A., Galetti, M., Terenziani, R., Eltayeb, K., Volta, F., Zoppi, S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.942341 · Cited by 24
Wu, J., Zong, Y., Fei, X., Chen, X., Huang, O., He, J., Chen, W., Li, Y., Shen, K., & Zhu, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098673 · Cited by 26
Prada, E. T. A., Nölting, S., Spoettl, G., Maurer, J., & Auernhammer, C. J. (2017) · Neuroendocrinology · doi:10.1159/000463386 · Cited by 29
CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer
Pan, Q., Sathe, A., Black, P. C., Goebell, P. J., Kamat, A. M., Schmitz‐Dräger, B. J., & Nawroth, R. (2017) · Bladder Cancer · doi:10.3233/blc-170105 · Cited by 28
Rencüzoğulları, Ö., Yerlikaya, P. O., Gürkan, A. Ç., Arısan, E. D., & Telci, D. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29249 · Cited by 30
Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo
Elango, R., Vishnubalaji, R., Manikandan, M., Binhamdan, S., Siyal, A., Alshawakir, Y. A., Alfayez, M. A., Aldahmash, A. M., & Alajez, N. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-50140-0 · Cited by 26
Targeting Cyclin-Dependent Kinases in Ovarian Cancer
Zhou, Q. (2017) · Cancer Investigation · doi:10.1080/07357907.2017.1283508 · Cited by 24
The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines
Lopes-Ventura, S., Pojo, M., Matias, A. T., Moura, M. M., Marques, I. J., Leite, V. A. P. H., & Cavaco, B. M. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0947-4 · Cited by 25
Decreased ER dependency after acquired resistance to CDK4/6 inhibitors
Iida, M., Toyosawa, D., Nakamura, M., Tsuboi, K., Tokuda, E., Niwa, T., Ishida, T., & Hayashi, S. (2020) · Breast Cancer · doi:10.1007/s12282-020-01090-3 · Cited by 26
Lee, J. S., Yost, S. E., Li, S. M., Cui, Y., Frankel, P. H., Yuan, Y., Schmolze, D., Egelston, C. A., Guo, W., Murga, M., et al. (2022) · Cancers · doi:10.3390/cancers14133159 · Cited by 27
Krasniqi, E., Goeman, F., Pulito, C., Palcau, A. C., Ciuffreda, L., Lisa, F. S. D., Filomeno, L., Barba, M., Pizzuti, L., Cappuzzo, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314534 · Cited by 23
Cuproptosis-related gene CDKN2A as a molecular target for IPF diagnosis and therapeutics
Xu, B., Yang, K., Han, X., & Hou, J. (2023) · Inflammation Research · doi:10.1007/s00011-023-01739-7 · Cited by 26
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays
Foy, R., Lew, K. X., & Saurin, A. T. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00624-8 · Cited by 29
Tanioka, M., Sakai, K., Sudo, T., Sakuma, T., Kajimoto, K., Hirokaga, K., Takao, S., Negoro, S., Minami, H., Nakagawa, K., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3121-5 · Cited by 25
Sini, V., Cinieri, S., Conte, P., Laurentiis, M. D., Leo, A. D., Tondini, C. A., & Marchetti, P. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.02.008 · Cited by 26
Pertuzumab for the treatment of breast cancer: a safety review
Gao, J. J., & Swain, S. M. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1167185 · Cited by 23
Rai, V. M., Pai, V. R., & Kedilaya, P. (2016) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2016.60811 · Cited by 23
Risi, E., Grilli, A., Migliaccio, I., Biagioni, C., McCartney, A., Guarducci, C., Bonechi, M., Benelli, M., Vitale, S., Biganzoli, L., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4766-2 · Cited by 27
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer
Agostinetto, E., Debien, V., Marta, G. N., Lambertini, M., Piccart, M. J., & de Azambuja, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13535 · Cited by 27
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Loibl, S., & Furlanetto, J. (2021) · The Breast · doi:10.1016/j.breast.2021.12.008 · Cited by 23
Escrivá-de-Romaní, S., Cejalvo, J. M., Alba, E., Friedmann, J. E., Rodríguez-Lescure, Á., Savard, M.-F., Pezo, R. C., Gion, M., Ruíz‐Borrego, M., Hamilton, E. P., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00140-8 · Cited by 28
Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer
Almstedt, K., & Schmidt, M. (2015) · Breast Care · doi:10.1159/000405017 · Cited by 22
Tancredi, R. J., Furlanetto, J., & Loibl, S. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0077 · Cited by 24
Das, A., Alshareef, M., Santos, J. L. M., Porto, G. B. F., McDonald, D. G., Infinger, L. K., Vandergrift, W. A., Lindhorst, S., Varma, A. K., Patel, S. J., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02341-7 · Cited by 22
Liao, H., & Li, H. (2020) · Cancer Management and Research · doi:10.2147/cmar.s249041 · Cited by 26
A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis
Krishnamurthy, J., Luo, J. R., Suresh, R., Ademuyiwa, F. O., Rigden, C. E., Rearden, T. P., Clifton, K., Weilbaecher, K. N., Frith, A. E., Roshal, A., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00399-w · Cited by 23
Yan, C., Gao, R., Gao, C., Hong, K., Cheng, M., Liu, X., Zhang, Q. H., & Zhang, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1105117 · Cited by 22
Zhao, S., Zhang, H., Yang, N., & Jin, Y. (2023) · Translational Cancer Research · doi:10.21037/tcr-22-2807 · Cited by 22
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, I., Abreu, C., Costa, L., & Casimiro, S. (2023) · Cancers · doi:10.3390/cancers15194835 · Cited by 27
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
Masci, D., Naro, C., Puxeddu, M., Urbani, A., Sette, C., Regina, G. L., & Silvestri, R. (2023) · Molecules · doi:10.3390/molecules28227513 · Cited by 34
Novel arylazopyrazole inhibitors of cyclin-dependent kinases
Jorda, R., Schütznerová, E., Cankař, P., Brychtová, V., Navrátilová, J., & Kryštof, V. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.025 · Cited by 22
Handa, T., Katayama, A., Yokobori, T., Yamane, A., Fujii, T., Obayashi, S., Kurozumi, S., Kawabata‐Iwakawa, R., Gombodorj, N., Nishiyama, M., et al. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4675 · Cited by 22
Huang, Y., Wu, H., & Li, X. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01597-x · Cited by 22
Updates on managing advanced breast cancer with palbociclib combination therapy
McShane, T. M., Wolfe, T. A., & Ryan, J. C. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918793849 · Cited by 21
Targeting CDK4/6 in mantle cell lymphoma
Lee, C. Y., Huang, X., Liberto, M. D., Martin, P., & Chen‐Kiang, S. (2020) · Annals of Lymphoma · doi:10.21037/aol.2019.12.01 · Cited by 20
Metadata
- Authors
- Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., Los, G., & Slamon, D. J.
- Affiliations
- University of California, Los Angeles (US)
- Pfizer (United States) (US)
- Corresponding author
- Finn, Richard S
- Venue
- Breast Cancer Research
- Published
- 2009-10-29
- Volume
- 11
- Issue
- 5
- Pages
- R77-R77
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- PMC
- PMC2790859
- OpenAlex
- W2148345265
- Cited by
- 1,398
- References
- 49
- Citations by year
- 2026: 48 · 2025: 76 · 2024: 64 · 2023: 94 · 2022: 115 · 2021: 121 · 2020: 137 · 2019: 128 · 2018: 137 · 2017: 131 · 2016: 105 · 2015: 92 · 2014: 51 · 2013: 42 · 2012: 28
- FWCI
- 15.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Breast Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Defense (W81XWH)
- Russian Science Foundation
- National Institutes of Health (W81XWH)
- Jonsson Comprehensive Cancer Center
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- palbociclib, CDK4/6 inhibitors, HER2-amplified breast cancer, retinoblastoma protein phosphorylation, cyclin D1, CDKN2A, p16, G0/G1 cell cycle arrest, drug sensitivity, drug resistance, patient selection, breast cancer cell lines
- MeSH terms
- Trastuzumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cell Cycle, Drug Synergism, Humans, Phosphorylation, Piperazines, Pyridines, Receptors, Estrogen, Tamoxifen, Retinoblastoma Protein, Apoptosis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Gene Expression Profiling, Cell Line, Tumor, Cell Growth Processes, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.